CONDENSED STATEMENTS OF OPERATIONS (Unaudited) (USD $) In Thousands, except Per Share data	3 Months Ended		9 Months Ended
	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011	Sep. 30, 2010
Revenues
Sanofi collaboration revenue	$ 79,802	$ 75,583	$ 249,577	$ 229,195
Other collaboration revenue	10,094	13,761	33,698	40,483
Technology licensing	5,893	10,037	18,966	30,112
Net product sales	5,468	4,936	14,934	19,985
Contract research and other	1,576	1,662	5,672	5,624
Total revenues	102,833	105,979	322,847	325,399
Expenses
Research and development	127,924	122,043	400,465	364,040
Selling, general, and administrative	32,916	15,658	80,912	44,560
Cost of goods sold	450	372	1,227	1,494
Total expenses	161,290	138,073	482,604	410,094
Loss from operations	(58,457)	(32,094)	(159,757)	(84,695)
Other income (expense)
Investment income	715	453	2,750	1,484
Interest expense	(4,061)	(2,234)	(11,827)	(6,660)
Total other income (expense)	(3,346)	(1,781)	(9,077)	(5,176)
Net loss before income tax expense (benefit)	(61,803)	(33,875)	(168,834)	(89,871)
Income tax expense (benefit)	562	0	(517)	0
Net loss	$ (62,365)	$ (33,875)	$ (168,317)	$ (89,871)
Net loss per share, basic and diluted	$ (0.68)	$ (0.41)	$ (1.87)	$ (1.10)
Weighted average shares outstanding, basic and diluted	91,046	81,638	90,215	81,433